Document Type : Original Article(s)
Authors
- Maedeh Vakili Saatloo 1
- Ahmad Yari Khosroushahi 2
- Yasmin Mohamadzadeh Gharebaghi 3
- Maryam Kouhsoltani 3
1 Department of Periodontology, Henry M. Goldman School of Dental Medicine, Boston University, MA, USA.
2 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Department of Medical Nanotechnology, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
Background: ROCK genes play an essential role in cancer development. The aim of the present study was to investigate a novel gene therapy approach by ROCK1 and ROCK2 genes silencing for head and neck squamous cell carcinoma (HNSCC) treatment.
Method: In this in-vitro study, two cell lines including HN5 for HNSCC and a normal cell line were treated with ROCK1 and ROCK2 siRNAs together or alone with or without cisplatin. MTS, the real time polymesrae chain reaction, 4′,6-diamidino-2-phenylindole (DAPI) staining, Enzyme-linked Immunosorbent Assay (ELISA) and flow cytometry tests were carried out.
Results: The highest level of apoptosis (88%) was seen in HN5 cells treated with ROCK2 siRNA, while this treatment revealed 1.08% apoptosis in normal cells. Cell viability decreased significantly to 0.31 after ROCK2 siRNA with cisplatin treatment and to 0.33 after ROCK1 / ROCK2 siRNA with cisplatin treatment in HN5. ROCK1 / ROCK2 genes silencing (especially ROCK2) increased apoptosis and decrease proliferation in HNSCC. The combination of ROCK2 siRNA and cisplatin demonstrated the greatest effect on apoptosis of cancerous cells. However, adding cisplatin to ROCK2 siRNA did not significantly increase apoptosis.
Conclusion: Based on our in-vitro data and due to the issue of cost and benefit, ROCK2 siRNA alone represents a potent and selective agent for the induction of apoptosis and inhibition of proliferation in HNSCC. Our findings suggest that ROCK1 / ROCK2 genes silencing (especially ROCK2) warrants further investigation as potential treatment strategy for HNSCC. Further studies are essential to support the translational potential of ROCK-targeted siRNA therapy.
Highlights
Maedeh Vakili Saatloo (google scholar)
Maryam Kouhsoltani (google scholar)
Keywords
Main Subjects
Please cite this article as: Vakili Saatloo M, Yari Khosroushahi A, Mohamadzadeh Gharebaghi Y, Kouhsoltani M. ROCK1 and ROCK2 siRNAs decrease proliferation and increase apoptosis in human head and neck squamous cell carcinoma. Middle East J Cancer. 2026: in press. doi: 10.30476/mejc.2026.106939.2278.
- Constantin M, Chifiriuc MC, Bleotu C, Vrancianu CO, Cristian RE, Bertesteanu SV, et al. Molecular pathways and targeted therapies in head and neck cancers pathogenesis. Front Oncol. 2024;14:1373821. doi: 10.3389/fonc.2024.1373821. PMID: 38952548; PMCID: PMC:11215092.
- Szturz P, Vermorken JB. Treatment of elderly patients with squamous cell carcinoma of the head and neck. Front Oncol. 2016;6:199. doi: 10.3389/fonc.2016.00199. PMID: 27630826; PMCID: PMC5006317.
- Hwang W, Ahn JS, Jung HA, Wirth LJ, Park JC. Emerging EGFR-targeted therapy in head and neck cancer: A review. JAMA Oncol. 2025. 11(11):1373-84. doi: 10.1001/jamaoncol.2025.3136. PMID: 40996745.
- Shahbazi R, Baradaran B, Khordadmehr M, Safaei S, Baghbanzadeh A, Jigari F, et al. Targeting ROCK signaling in health, malignant and non-malignant diseases. Immunol Lett. 2020;219:15-26. doi: 10.1016/j.imlet.2019.12.012. PMID: 31904392.
- Qin Z, Wei X, Jin N, Wang Y, Zhao R, Hu Y, et al. MiR-199a targeting ROCK1 to affect kidney cell proliferation, invasion and apoptosis. Artif Cells Nanomed Biotechnol. 2018;46(8):1920-5. doi: 10.1080/21691401.2017.1396224. PMID: 29130345.
- Rath N, Olson MF. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep. 2012;13:900–8. doi: 10.1038/embor.2012.127. PMID: 22964758; PMCID: PMC3463970.
- Irimie AI, Braicu C, Sonea L, Zimta AA, Cojocneanu-Petric R, Tonchev K, et al. A looking-glass of non-coding RNAs in oral cancer. Int J Mol Sci. 2017;18(12):2620. doi: 10.3390/ijms18122620. PMID: 29206174; PMCID: PMC5751223.
- Pinca RS, Manara MC, Chiadini V, Picci P, Zucchini C, Scotlandi K. Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy. Oncol Rep. 2017;37:1387-93. doi: 10.3892/or.2017.5397. PMID: 28112365; PMCID: PMC5364828.
- Thompson JM, Nguyen QH, Singh M, Pavesic MW, Nesterenko I, Nelson LJ, et al. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Oncogene. 2017;36(8):1080-9. doi: 10.1038/onc.2016.272. PMID: 27841867; PMCID: PMC5323317.
- Chan GK, Kleinheinz TL, Peterson D, Moffat JG. A simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assays. PLoS One. 2013;8:e63583. doi: 10.1371/journal.pone.0063583. PMID: 23691072; PMCID: PMC3656927.
- Tabatabaei MS, Ahmed M. Enzyme-linked immunosorbent assay (ELISA). Methods Mol Biol. 2022;2508:115-34. doi: 10.1007/978-1-0716-2376-3_10. PMID: 35737237.
- Garcia-Bermejo ML, Leskow FC, Fujii T, Wang Q, Blumberg PM, Ohba M, et al. Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by selective activation of PKCalpha. J Biol Chem. 2002;277:645-55. doi: 10.1074/jbc.M107639200. PMID: 11584014.
- Patnaik S, Mallick R, Kannisto E, Sharma R, Bshara W, Yendamuri S, et al. MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies. J Thorac Oncol. 2015;10:446-53. doi: 10.1097/jto.0000000000000423. PMID: 25695220; PMCID: PMC5819754.
- Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014;5:e29846. doi: 10.4161/sgtp.29846. PMID: 25010901; PMCID: PMC4114931.
- Ma W, Sze KM, Chan LK, Lee JM, Wei LL, Wong CM, et al. RhoE/ROCK2 regulates chemoresistance through NF-κB/IL-6/ STAT3 signaling in hepatocellular carcinoma. Oncotarget. 2016;7:41445-59. doi: 10.18632/oncotarget.9441. PMID: 27213590; PMCID: PMC5173071.
- Glotfelty EJ, Tovar-Y-Romo LB, Hsueh SC, Tweedie D, Li Y, Harvey BK, et al. The RhoA-ROCK1/ROCK2 pathway exacerbates inflammatory signaling in immortalized and primary microglia. Cells. 2023;12(10):1367. doi: 10.3390/cells12101367. PMID: 37408199; PMCID: PMC10216802.
- Whatcott CJ, Ng S, Barrett MT, Hostetter G, Von Hoff DD, Han H. Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer. PLoS One. 2017;12(8):e0183871. doi: 10.1371/journal.pone.0183871. PMID: 28841710; PMCID: PMC5571985.
- Inaba N, Ishizawa S, Kimura M, Fujioka K, Watanabe M, Shibasaki T, et al. Effect of inhibition of the ROCK isoform on RT2 malignant glioma cells. Anticancer Res. 2010;30:3509-14. PMID: 20944130.
- Yao J, Gao P, Xu Y, Li Z. α-TEA inhibits the growth and motility of human colon cancer cells via targeting RhoA/ROCK signaling. Mol Med Rep. 2016;14:2534-40. doi: 10.3892/mmr.2016.5525. PMID: 27432222; PMCID: PMC4991732.
- Kular J, Scheer KG, Pyne NT, Allam AH, Pollard AN, Magenau A, et al. A negative regulatory mechanism involving 14-3-3ζ limits signaling downstream of ROCK to regulate tissue stiffness in epidermal homeostasis. Dev Cell. 2015;35(6):759-74. doi: 10.1016/j.devcel.2015.11.026. PMID: 26702834.
- Saito K, Sakaguchi M, Iioka H, Matsui M, Nakanishi H, Huh NH, et al. Coxsackie and adenovirus receptor is a critical regulator for the survival and growth of oral squamous carcinoma cells. Oncogene. 2014;33:1274-86. doi: 10.1038/onc.2013.66. PMID: 23503462.
- Tilson SG, Haley EM, Triantafillu UL, Dozier DA, Langford CP, Gillespie GY, et al. ROCK inhibition facilitates in vitro expansion of glioblastoma stem-like cells. PLoS One. 2015;10:e0132823. doi: 10.1371/journal.pone.0132823. PMID: 26167936; PMCID: PMC4500389.
- Miyazaki J, Ito K, Fujita T, Matsuzaki Y, Asano T, Hayakawa M, et al. Progression of human renal cell carcinoma via inhibition of RhoA-ROCK axis by PARG1. Transl Oncol. 2017;10:142-52. doi: 10.1016/j.tranon.2016.12.004. PMID: 28131798; PMCID: PMC5284488.
- Zandvakili I, Lin Y, Morris JC, Zheng Y. Rho GTPases: Anti- or pro-neoplastic targets? Oncogene. 2017;36:3213-22. doi: 10.1038/onc.2016.473. PMID: 27991930; PMCID: PMC5464989.
)